Company Overview and News
The Progressive Corporation’s (PGR - Free Report) third-quarter 2018 operating earnings per share of $1.32 beat the Zacks Consensus Estimate of $1.14. The bottom line skyrocketed about 178% year over year.
BRK.A CINF PGR MKL
2018-10-16 zacks - 1
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the First Trust Capital Strength ETF (FTCS - Free Report) , a passively managed exchange traded fund launched on 07/06/2006.
IVV PFZ PGR CTRL CI IVV 500680 PFE PFIZER
2018-10-16 sec.gov - 2
The Progressive Corporation (PGR - Free Report) is slated to report third-quarter 2018 results on Oct 16 before market open. The company has a solid track of delivering a positive surprise in each of the last four quarters. Factors to be Considered in Q3 Progressive is expected to have witnessed another quarter of sturdy policies in force across all its business lines, driving premiums higher. This coupled with improved investment income (attributable to sustained rate hikes) and higher service revenues and fees as well as other revenues should have fueled top-line improvement in the to be reported quarter.
CBSH TMK CBSHP RNR PGR MTG TMK CBCB
Chicago, IL – October 11, 2018 - Stocks in this week’s article are The Marcus Corp. (MCS - Free Report) , Dick's Sporting Goods Inc. (DKS - Free Report) , The Progressive Corp. (PGR - Free Report) , Matson Inc. (MATX - Free Report) and Tractor Supply Co. (TSCO - Free Report) .
STZ.B TSCO DKS PGR MATX STZ URBN
Estimates for The Progressive Corporation (PGR - Free Report) have been revised upward over the past seven days, reflecting analysts’ confidence in the stock before earnings. The Zacks Consensus Estimate for 2018 earnings moved 1.3% north to $4.69 in the said timeframe. This leading auto insurer sports a Zacks Rank #1 (Strong Buy) and has an impressive VGM Score of A. Back-tested results have shown that stocks with a favorable VGM Score of A or B coupled with a solid Zacks Rank #1 or 2 (Buy) offer the best investment opportunity.
RNR PGR KINS MKL
Progressive (PGR - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The U.S. equity markets remained highly volatile over the past week as yields from the treasury bonds inched up with solid macroeconomic fundamentals. Per the latest jobs report, unemployment rate declined to a 49-year low of 3.7%, fuelling speculations of a likely Fed hike later this year and up to four times in 2019. With the earnings season set to gradually pick up pace in the forthcoming weeks, the markets are anticipated to witness another round of volatility owing to lesser-than-expected performance from the banking sector.
CBG AVGO PGR WM BRCM CBRE CE
Chicago, IL – October 8, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United Insurance Holdings Corp. (UIHC - Free Report) , The Progressive Corp. (PGR - Free Report) , James River Group Holdings, Ltd.
WFCNP HD FRC PGR JRVR AMP UIHC MO WFC SMPL OZK AZPN BYD
Given a substantial improvement in the economy, backed by rising interest rates, a growing gross domestic product (GDP) and lower tax incidence, the insurance industry has so far been exhibiting a significantly favorable performance. We expect this momentum to continue in the fourth quarter based on the aforementioned factors, which will enable insurers to focus on bolstering their bottom line as well as boosting top-line growth.
IP INPAP PGR JRVR UIHC
The Finance sector is set to kick off its earnings season next week with major banks reporting quarterly results. Per the Earnings Outlook, Finance is one of those 10 Zacks sectors that are set to deliver double-digit earnings growth. Earnings for the sector are expected to increase 29.5% on 3.2% higher revenues. An improving rate environment and tax cuts should continue to drive the sector’s performance.
TMK AFW ATH RNR AFGE RDN PGR AFA AFGH TMK AFG CSBR HIG FAF CI HGH UIHC
In January, I began publishing articles that examined how far several large-cap industrial stocks might fall during a bear market, and I suggested some alternative investments.
STT GD CAT PGR VPU UTX CMI ETN FISV NOC JNJ ROK
Have you been paying attention to shares of The Progressive (PGR - Free Report) ? Shares have been on the move with the stock up 4.7% over the past month. The stock hit a new 52-week high of $71.77 in the previous session. The Progressive has gained 25.5% since the start of the year compared to the -2% move for the Zacks Finance sector and the 6.5% return for the Zacks Insurance - Property and Casualty industry.
Investors focused on the Finance space have likely heard of The Progressive (PGR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET